This trial aims to see if combining two medications, pembrolizumab (Keytruda) and RO7198457 (a new experimental vaccine) is better than just using pembrolizumab in treating advanced melanoma that has not been treated before. The main outcome that will be measured is how long the patients go without cancer growing. The study is being conducted in the United States and Australia.
The details
There are a number of treatments for melanoma. RO7198457 is a personalized cancer vaccine which is currently being developed. It is not known if treating patients with pembrolizumab and RO7198457 is better than treating them with just pembrolizumab alone.
This trial aims to see if combining two medications, pembrolizumab and RO7198457 is better than pembrolizumab alone in treating advanced melanoma that has not been treated before. The main outcome that will be measured is survival without cancer growing or spreading.
Who are they looking for?
This trial is recruiting 132 patients. To be included in this trial, patients must have adequate organ functions.
Patients are not allowed in the trial if they have been treated before for melanoma, or if they have an actively progressing cancer in the brain, a history of autoimmune disease, or an active infection. Patients who have had their spleen removed, a bone marrow transplant, or heart or liver disease will also be excluded.
How will it work
This trial will consist of two groups. One group will receive treatment with pembrolizumab and RO7198457. The other group will only receive treatment with pembrolizumab. They will be assessed to see how well the treatment works, how long it takes for cancer to grow, and how safe the treatment is for up to 2 years.
